Show simple item record

dc.contributor.authorSoriano, Vicente
dc.contributor.authorBarreiro, Pablo
dc.contributor.authorCachay, Edward
dc.contributor.authorKottilil, Shyamasundaran
dc.contributor.authorFernandez-Montero, José V.
dc.contributor.authorde Mendoza, Carmen
dc.date.accessioned2020-10-27T18:56:15Z
dc.date.available2020-10-27T18:56:15Z
dc.date.issued2020-10-15
dc.identifier.urihttp://hdl.handle.net/10713/13953
dc.description.abstractDespite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of hepatocellular carcinoma, which represents the third cause of cancer mortality, accounting for nearly 1 million annual deaths. Current oral nucleos(t)ide therapy with tenofovir or entecavir suppresses serum HBV-DNA in most treated patients, but rarely is accompanied by HBsAg loss. Thus, treatment has to be given lifelong to prevent viral rebound. A broad spectrum of antivirals that block the HBV life cycle at different steps are in clinical development, including entry inhibitors, cccDNA disrupters/silencers, translation inhibitors, capsid assembly modulators, polymerase inhibitors and secretion inhibitors. Some of them exhibit higher potency than current oral nucleos(t)ides. Drugs in more advanced stages of clinical development are bulevirtide, JNJ-6379, ABI-H0731, ARO-HBV and REP-2139. To date, only treatment with ARO-HBV and with REP-2139 have resulted in HBsAg loss in a significant proportion of patients. Combination therapies using distinct antivirals and/or immune modulators are expected to maximize treatment benefits. The current goal is to achieve a ‘functional cure’, with sustained serum HBsAg after drug discontinuation. Ultimately, the goal of HBV therapy will be virus eradication, an achievement that would require the elimination of the cccDNA reservoir within infected hepatocytes. © The Author(s), 2020.en_US
dc.description.urihttps://doi.org/10.1177/2049936120965027en_US
dc.language.isoenen_US
dc.publisherSAGE Publications Inc.en_US
dc.relation.ispartofTherapeutic Advances in Infectious Diseaseen_US
dc.subjectantiviral therapyen_US
dc.subjectbulevirtideen_US
dc.subjectcccDNAen_US
dc.subjectchronic hepatitis Ben_US
dc.subjectcombination therapyen_US
dc.subjectgene editingen_US
dc.subjecthepatitis deltaen_US
dc.subjectresistanceen_US
dc.titleAdvances in hepatitis B therapeuticsen_US
dc.typeArticleen_US
dc.identifier.doi10.1177/2049936120965027
dc.source.volume7


This item appears in the following Collection(s)

Show simple item record